Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) COO Weiguo Ye sold 9,400 shares of the stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $6.15, for a total value of $57,810.00. Following the completion of the sale, the chief operating officer directly owned 700,000 shares of the company’s stock, valued at approximately $4,305,000. The trade was a 1.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Weiguo Ye also recently made the following trade(s):
- On Thursday, May 21st, Weiguo Ye sold 12,820 shares of Gyre Therapeutics stock. The stock was sold at an average price of $6.15, for a total transaction of $78,843.00.
Gyre Therapeutics Price Performance
NASDAQ GYRE traded down $0.12 on Friday, hitting $6.06. 86,973 shares of the stock were exchanged, compared to its average volume of 90,296. The company has a market capitalization of $588.00 million, a PE ratio of -67.33 and a beta of 2.03. The business’s fifty day moving average is $7.29 and its 200 day moving average is $7.61. Gyre Therapeutics, Inc. has a 52 week low of $5.97 and a 52 week high of $11.61.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on GYRE. Wall Street Zen cut Gyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings cut shares of Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Finally, Zacks Research cut shares of Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, March 16th. Two research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $17.00.
Get Our Latest Research Report on GYRE
Hedge Funds Weigh In On Gyre Therapeutics
Institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its holdings in shares of Gyre Therapeutics by 40.4% during the 4th quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock worth $84,000 after buying an additional 1,996 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Gyre Therapeutics by 28.6% during the 2nd quarter. Geode Capital Management LLC now owns 401,709 shares of the company’s stock worth $2,953,000 after buying an additional 89,390 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Gyre Therapeutics by 84.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after buying an additional 2,961 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Gyre Therapeutics by 77.8% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock worth $54,000 after buying an additional 3,244 shares in the last quarter. Finally, State of Alaska Department of Revenue bought a new position in shares of Gyre Therapeutics during the 3rd quarter worth approximately $38,000. 23.99% of the stock is owned by institutional investors and hedge funds.
Gyre Therapeutics Company Profile
Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.
Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.
Read More
- Five stocks we like better than Gyre Therapeutics
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
